# Bajaj Healthcare share price today (Bajaj Healthcare Ltd, NSE: BAJAJHCARE)

> Bajaj Healthcare share price today: ₹306.10 at the NSE close on 3 November 2026, down 35.6% in a year. Bajaj Healthcare (NSE: BAJAJHCARE) is worth ₹1,031 crore, trades at a P/E of 17.7 and has closed between ₹284.45 and ₹448.40 over the past 52 weeks. > Bajaj Healthcare Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. BAJAJHCARE · Pharma - Formulators · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from fewer quarters than usual
- Price: ₹306.10 (−35.6% in a year)
- P/E: 17.7× (lower than 62% of the last 11 years)
- Revenue (Sep 2026): ₹176 Cr (+18.9% on a year ago)
- Profit (Sep 2026): ₹14.0 Cr (+27.3% on a year ago)
- Operating margin: 18.0% (flat on a year ago)
- ROCE: 11%, FY26
- ROIC: 8.0%, against a 12.0% cost of capital: −4.0 points

The main question: profits are rising, but only 59% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the Bajaj Healthcare share price today? Bajaj Healthcare Ltd's share price was ₹306.10 at the close on 3 November 2026. It has been falling for 66 weeks. That is 11.5% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹284 and ₹448, and at that close it sat 13% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 1 week in a row. Over the last 11 years the share price moved +608% while the NIFTY 500 moved +231%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Bajaj Healthcare this quarter? One change stood out: highest quarterly revenue in 16 quarters. 1. Highest quarterly revenue in 16 quarters Revenue of ₹176 crore in the September 2026 quarter is the highest of the last 16 quarters. Why: Revenue hit its highest level in 16 quarters because the company sold more medicine ingredients abroad and more finished medicine products. That more than covered weaker sales of ingredients in India. Next results: check whether Cenobamate repeat orders turn into steady demand, because management said early stocking was more than regular demand. From the earnings call on 19 Oct 2026. ## What are Bajaj Healthcare's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Bajaj Healthcare reported revenue of ₹176 crore, up 18.9% from ₹148 crore a year earlier, and a profit of ₹14.0 crore, up 27.3% from ₹11.0 crore. ### Bajaj Healthcare results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹176 crore | ₹148 crore | +18.9% |
| Profit | ₹14.0 crore | ₹11.0 crore | +27.3% |
| Earnings per share | ₹4.19 | ₹3.52 | +19.0% |
| Operating margin | 18.0% | 18.0% | 0.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Bajaj Healthcare's management discussed these results on a call held on 19 October 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Bajaj Healthcare share price history? Bajaj Healthcare closed at ₹306.10 on 3 November 2026, down 35.6% from ₹475.55 a year earlier (31 October 2025) and down 19.9% over five years. Its highest weekly close since May 2016 was ₹708.85 on 21 March 2025. ### Bajaj Healthcare share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹312.65 | −2.1% |
| 1 month ago · 1 Oct 2026 | ₹323.40 | −5.3% |
| 6 months ago · 30 Apr 2026 | ₹322.00 | −4.9% |
| 1 year ago · 31 Oct 2025 | ₹475.55 | −35.6% |
| 3 years ago · 3 Nov 2023 | ₹412.45 | −25.8% |
| 5 years ago · 4 Nov 2021 | ₹382.25 | −19.9% |
| 10 years ago · 4 Nov 2016 | ₹61.53 | +397.5% |
| Earliest weekly close in our records · 13 May 2016 | ₹43.23 | +608.1% |
| Highest weekly close since May 2016 · 21 Mar 2025 | ₹708.85 | −56.8% |
| Lowest weekly close since May 2016 · 24 Jun 2016 | ₹43.00 | +611.9% |
| 52-week high (weekly close) · 14 Nov 2025 | ₹448.40 | −31.7% |
| 52-week low (weekly close) · 13 Mar 2026 | ₹284.45 | +7.6% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (537 weekly closes from 13 May 2016 to 3 November 2026.)

## What is the latest news on Bajaj Healthcare? 3 Nov 2026: Bajaj Healthcare closed at ₹306.10, down 2.1% on the week and down 5.3% on the month. 19 Oct 2026: Bajaj Healthcare held its results call for July to September 2026. Management guided: FY29 revenue ₹900-1,000 crore and operating margin 18%-21%. ### Earlier

- Results for July to September 2026: Revenue up 18.9% and profit up 27.3% on a year earlier. - 11 Sep 2026: ex-date for a dividend of ₹1.50 a share, record date 14 Sep 2026. ## What dividend does Bajaj Healthcare pay? Bajaj Healthcare paid ₹1.50 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.49% at the ₹306.10 close on 3 November 2026. The last was a dividend of ₹1.50 a share, ex-date 11 September 2026. ### Bajaj Healthcare dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 11 Sep 2026 | ₹1.50 | Dividend | 14 Sep 2026 |
| 19 Sep 2025 | ₹1 | Dividend | same day |
| 23 Sep 2024 | ₹1 | Dividend | n/a |
| 22 Sep 2023 | ₹1 | Dividend | n/a |
| 22 Sep 2022 | ₹1.50 | Dividend | n/a |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 4 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Bajaj Healthcare Ltd paid out 32% of its profit as dividends in FY26, and it paid a dividend in 6 of its last 13 reported years. One of those years shows a negative figure because profit itself was negative. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Bajaj Healthcare management say on the latest results call? On the call for July to September 2026, held on 19 October 2026, Bajaj Healthcare's management guided: FY29 revenue ₹900-1,000 crore and operating margin 18%-21%. > “Once we start commercial production, which, as I mentioned, will be in Q2 FY28, it will take another 6-10 months to receive approvals from customers.”
> Anil Jain, on the call for July to September 2026

### What management guided

- FY27 revenue and profit growth of 10%-15%, with operating margin of 18%-20%, reaffirmed as on track. - FY27 capital spending ₹65-80 crore, annual capital spending ₹50-60 crore thereafter, and FY27 operating cash flow above ₹30 crore. - Peptide plant capacity 250 kg/year; completion by March 2027, commercial production in July to September 2027, customer approvals another 6-10 months; first-year revenue ₹70-100 crore and cumulative revenue around ₹300 crore the following year. - Genrx/Nashik facility expected operational in April to June 2027; revenue potential ₹200-250 crore over the next 2-3 years. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/5835/Conference Call/CC-Oct26.pdf). (From the call for July to September 2026, 19 October 2026.)

## What to watch in Bajaj Healthcare's next results? When Bajaj Healthcare reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Peptide construction and customer-approval progress - check movement toward commercial production and customer readiness. - What to check (from the call)
- Peptide construction and customer-approval progress - check movement toward commercial production and customer readiness. - Genrx implementation and operating readiness - check progress from NCLT approval toward production. - West Asia inventory buffer and receivable turnover - check whether cash conversion improves as supply uncertainty evolves. ## Which stock lists is Bajaj Healthcare on? Bajaj Healthcare is on one of our India lists: Pharma stocks. [Pharma stocks Market value (₹ crore): 1032.6829905321579](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Bajaj Healthcare profitable? Bajaj Healthcare Ltd earned ₹14.0 Cr of net profit in the Sep 2026 quarter, +27.3% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹16.0 Cr. Over 10 years profit has grown 7.2% a year on average. That is 8.0% of the quarter's revenue. The same quarter a year earlier earned ₹11.0 Cr. 3 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was ₹16.0 Cr (−60.0% on the year before). Why profit moved: revenue changed +18.9% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed −58.0% and revenue +15.1%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Bajaj Healthcare make, and is it growing? Bajaj Healthcare Ltd reported ₹176 Cr of revenue in the Sep 2026 quarter, +18.9% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 10 years it has grown 10.6% a year on average. The last full year, FY26, came in at ₹611 Cr. The last four reported quarters add to ₹656 Cr. FY26 revenue was ₹611 Cr, +12.5% on the year before. Recent pace: the last four quarters grew +15.1% on average, against 10.6% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +14.3%, against +13.6% a year over the last 8 quarters (stabilising). ## How much of every ₹100 of sales does Bajaj Healthcare keep? Bajaj Healthcare Ltd's operating margin was 18.0% in the Sep 2026 quarter, about the same as the same quarter a year ago. Across 13 years it has been between 9.0% and 21.0%. The latest quarter is within that range. In the latest quarter it moved +0.0 percentage points on the same quarter a year ago. Why the margin moved: operating margin changed −0.5 percentage points on the year while gross margin changed −2.2 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Bajaj Healthcare's profit turning into cash? Over the last 3 years, 59% of Bajaj Healthcare Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹58.0 Cr of operating cash against ₹16.0 Cr of profit. After ₹43.0 Cr of spending on assets, ₹15.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 59% of profit came in as cash: the cash cycle got 174 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: it has been selling more assets than it buys. The next section shows those figures. ## Where does Bajaj Healthcare's cash go? Bajaj Healthcare Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 256 days in FY26, up from 82 days in FY21. Over the last 3 years it sold more assets than it bought, by ₹48.0 Cr. Customers take 140 days to pay, and stock sits for 249 days on average. At FY26 sales of ₹611 Cr, each day of that cycle ties up about ₹1.7 Cr, so roughly ₹429 Cr is tied up in the business at any time. FY26: customers took 140 days to pay and stock sat for 249 days, about 8.2 months of sales sitting as stock, for a full cycle of 256 days, longer than FY21's 82. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 249 days. Customers pay about 140 days after that. Suppliers are paid at 133 days. Together that makes the 256-day cycle. Over the last 3 years, money from selling assets was ₹48.0 Cr more than it spent on new ones. Work still in progress is ₹8.0 Cr (FY26). In short: assets are being sold, not built, so this cash is not going into new capacity. ## What is Bajaj Healthcare's P/E ratio, and how does it compare with its own history? Bajaj Healthcare Ltd's P/E is 17.7×, in the middle of its own history: higher than 38% of past readings. Its usual P/E (the middle reading) is 20.1×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −62.6% while the price moved −35.6%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved −4.3% a year; about −11.3% a year came from earnings growth and about +7.0 percentage points from the multiple (the market paying more); over 10 years the price moved +17.4% a year; about +19.2% a year came from earnings growth and about −1.8 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Bajaj Healthcare business getting better or worse? Bajaj Healthcare Ltd's business is giving mixed signals. There is no clear direction across the growth lines, with ROCE falling at 8.8%; each line tells part of the story. This is based on 12 quarters of 3 measures, with some gaps. Why it matters: when the lines disagree, each line above matters more than any single label. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Bajaj Healthcare earn on its capital? Bajaj Healthcare Ltd earned a ROCE of 11% in FY26. That is up from a low of 8% in FY24. Its return on capital used (ROIC) is 4.0 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 2.6% net margin and 0.66× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 2.6% net margin × 0.66× asset turnover × 1.73× leverage (assets divided by equity) ≈ 3.0% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 8.0% − 12.0% = −4.0 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Bajaj Healthcare have too much debt? Bajaj Healthcare Ltd has total debt of ₹282 Cr against shareholder equity of ₹557 Cr as of Sep 2026, so its debt is 0.51× its equity. Year by year, that ratio went from 0.78 in FY22 to 0.47 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Bajaj Healthcare shareholding pattern? Foreign institutions raised their stake in Bajaj Healthcare Ltd by 1.0 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 2.1% of the company. Promoters moved −0.6 points over the same period, to 58.6%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: +1.0 points over 8 quarters, to 2.1%; Promoters: −0.6 points over 8 quarters, to 58.6%; Domestic institutions: +0.0 points over 8 quarters, to 2.0%. Why the owners changed: foreign institutions drove it (+1.0 points), with the other side taken by promoters (−0.6 points). They raised their stake step by step. ## How far is Bajaj Healthcare from balance-sheet trouble? For Bajaj Healthcare Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Bajaj Healthcare rank in its industry? 46.5 out of 100, rank 25 of 44 in Pharma - Formulators, with 100% of the evidence available. Bajaj Healthcare Ltd scores 46.5 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 25. The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. The four parts add up to the total exactly: 15.2 + 10 + 16.6 + 4.7 = 46.5. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Bajaj Healthcare compared with? Bajaj Healthcare ranks 25 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 46.5 out of 100. 1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · leader · Most evidence points up · 83% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 46.8% · Profit 91.4% · Operating margin change 2 points · 88% evidence Capital efficiency 18.6/25 · ROCE 28.4% · Operating margin 24% · 100% evidence Valuation 6.2/20 · P/E 92.5× · PEG 2.31 · 65% evidence Relative strength 16.5/20 · Lead over its industry 28.1% · Lead over NIFTY 500 53.6% · 1 year 160.5% · 70% evidence · 11 of 12 weeks ahead Exact sum: 30.1 + 18.6 + 6.2 + 16.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 81% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.9/35 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 88% evidence Capital efficiency 18.2/25 · ROCE 24.1% · Operating margin 25% · 100% evidence Valuation 11.0/20 · P/E 44.2× · PEG 0.54 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 74.4% · 1 year 288.9% · 25% evidence · 9 of 9 weeks ahead Exact sum: 29.9 + 18.2 + 11 + 12.3 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · leader · Most evidence points up · 65% evidence 70.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.4/25 · ROCE 24.9% · Operating margin 24% · 100% evidence Valuation 9.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 18.6/20 · Lead over its industry 21.4% · Lead over NIFTY 500 47.6% · 1 year 132.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 21.4 + 9.1 + 18.6 = 70.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · leader · Most evidence points up · 100% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.3/25 · ROCE 34.5% · Operating margin 31% · 100% evidence Valuation 7.1/20 · P/E 34.7× · PEG 1.77 · 100% evidence Relative strength 10.5/20 · Lead over its industry -3.5% · Lead over NIFTY 500 20% · 1 year 42.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.3 + 21.3 + 7.1 + 10.5 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Most evidence points up · 86% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 32.9% · Profit 100% · Operating margin change 2 points · 88% evidence Capital efficiency 20.3/25 · ROCE 39.8% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 20.8× · PEG n/a · 50% evidence Relative strength 8.6/20 · Lead over its industry -11.4% · Lead over NIFTY 500 10.8% · 1 year 21.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 29.1 + 20.3 + 11.2 + 8.6 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.3/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.7/25 · ROCE 16.9% · Operating margin 26% · 76% evidence Valuation 6.4/20 · P/E 42.4× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 59% · Lead over NIFTY 500 86.2% · 1 year 312.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.3 + 14.7 + 6.4 + 16.7 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · breaking out · Most evidence points up · 76% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.9/43.75 · Revenue 50.3% · Profit 91.3% · Operating margin change 0 points · 88% evidence Capital efficiency 19.0/31.25 · ROCE 21.5% · Operating margin 14% · 100% evidence Valuation 14.9/25 · P/E 52.7× · PEG 0.77 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 8. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Most evidence points up · 89% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 28.2% · Profit 49.2% · Operating margin change 2 points · 88% evidence Capital efficiency 19.4/25 · ROCE 29.9% · Operating margin 30% · 100% evidence Valuation 16.1/20 · P/E 15.4× · PEG 0.54 · 65% evidence Relative strength 2.0/20 · Lead over its industry -24.5% · Lead over NIFTY 500 -4.7% · 1 year 2.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.9 + 19.4 + 16.1 + 2 = 65.4 · What this means: Earnings are strong; relative strength in its sector is -24.5% and the one-year return is 2.4%. 9. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · turning · Most evidence points up · 78% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 10.6% · Profit 68% · Operating margin change 6 points · 83% evidence Capital efficiency 15.7/25 · ROCE 17% · Operating margin 24% · 76% evidence Valuation 11.0/20 · P/E 35.6× · PEG n/a · 50% evidence Relative strength 14.7/20 · Lead over its industry -0.5% · Lead over NIFTY 500 23.6% · 1 year 51.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24 + 15.7 + 11 + 14.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · leader · Evidence leans up · 74% evidence 64.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 19.6% · Profit 48% · Operating margin change 9 points · 88% evidence Capital efficiency 17.2/25 · ROCE 18.8% · Operating margin 25% · 100% evidence Valuation 6.3/20 · P/E 26.8× · PEG 2.85 · 65% evidence Relative strength 11.9/20 · Lead over its industry n/a · Lead over NIFTY 500 40.1% · 1 year 68.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 17.2 + 6.3 + 11.9 = 64.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · basing · Evidence leans up · 85% evidence 62.8 out of 100 Growth Capital Valuation Relative
12. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · turning · Evidence leans up · 73% evidence 62.5 out of 100 Growth Capital Valuation Relative
13. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · losing its lead · Evidence leans up · 71% evidence 61.8 out of 100 Growth Capital Valuation Relative
14. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Evidence leans up · 100% evidence 61.0 out of 100 Growth Capital Valuation Relative
15. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · leader · Evidence leans up · 96% evidence 58.1 out of 100 Growth Capital Valuation Relative
16. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 71% evidence 56.2 out of 100 Growth Capital Valuation Relative
17. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.1 out of 100 Growth Capital Valuation Relative
18. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 75% evidence 55.3 out of 100 Growth Capital Valuation Relative
19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · losing its lead · Evidence leans up · 96% evidence 54.3 out of 100 Growth Capital Valuation Relative
20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 71% evidence 52.8 out of 100 Growth Capital Valuation Relative
21. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · breaking out · Evidence leans up · 78% evidence 51.3 out of 100 Growth Capital Valuation Relative
22. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · leader · Evidence leans up · 71% evidence 50.9 out of 100 Growth Capital Valuation Relative
23. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 78% evidence 47.6 out of 100 Growth Capital Valuation Relative
24. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · turning · Evidence leans down · 81% evidence 46.9 out of 100 Growth Capital Valuation Relative
25. Bajaj Healthcare Ltd this page BAJAJHCARE · quiet · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.2/35 · Revenue 14.3% · Profit -54.4% · Operating margin change 0 points · 100% evidence Capital efficiency 10.0/25 · ROCE 11.5% · Operating margin 18% · 100% evidence Valuation 16.6/20 · P/E 17.7× · PEG 0.56 · 100% evidence Relative strength 4.7/20 · Lead over its industry -27.1% · Lead over NIFTY 500 -7% · 1 year -35.6% · 100% evidence · 6 of 12 weeks ahead Exact sum: 15.2 + 10 + 16.6 + 4.7 = 46.5 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 26. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 100% evidence 46.0 out of 100 Growth Capital Valuation Relative
27. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.9 out of 100 Growth Capital Valuation Relative
28. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans down · 96% evidence 45.7 out of 100 Growth Capital Valuation Relative
29. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · turning · Evidence leans down · 96% evidence 44.9 out of 100 Growth Capital Valuation Relative
30. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 100% evidence 43.1 out of 100 Growth Capital Valuation Relative
31. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 42.6 out of 100 Growth Capital Valuation Relative
32. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 71% evidence 42.2 out of 100 Growth Capital Valuation Relative
33. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
34. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · turning · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
35. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Evidence leans down · 96% evidence 38.8 out of 100 Growth Capital Valuation Relative
36. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 74% evidence 35.8 out of 100 Growth Capital Valuation Relative
37. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · turning · Evidence leans down · 100% evidence 35.4 out of 100 Growth Capital Valuation Relative
38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · losing its lead · Most evidence points down · 100% evidence 34.6 out of 100 Growth Capital Valuation Relative
39. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · quiet · Most evidence points down · 96% evidence 34.4 out of 100 Growth Capital Valuation Relative
40. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
41. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative
42. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.3 out of 100 Growth Capital Valuation Relative
43. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · losing its lead · Too little evidence to rank firmly · 49% evidence 38.4 out of 100 Growth Capital Valuation Relative
44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · turning · Too little evidence to rank firmly · 31% evidence 36.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Bajaj Healthcare in size? Bajaj Healthcare is the 39th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Amrutanjan Health Care, Bharat Parenterals and Bafna Pharmaceuticals. Just below it: Lincoln Pharmaceuticals, Zim Laboratories and Kilitch Drugs (India). ### Pharma - Formulators companies close in size

1. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) ₹1,436 crore
2. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) ₹1,399 crore
3. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) ₹1,060 crore
4. Bajaj Healthcare Ltd ₹1,031 crore
5. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) ₹1,000 crore
6. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ₹731 crore
7. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) ₹704 crore

[All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies)

### Companies close in size in other industries

1. [Foseco Crucible (India) Ltd](https://www.sectoralpha.in/stocks/foseco-crucible-indialtd) ₹1,032 crore · Refractories
2. [Iris Clothings Ltd](https://www.sectoralpha.in/stocks/iris-clothings-ltd) ₹1,032 crore · Textiles - Readymade Apparel
3. Bajaj Healthcare Ltd ₹1,031 crore
4. [India Homes Ltd](https://www.sectoralpha.in/stocks/india-homes-ltd) ₹1,031 crore · Realty - Regional
5. [GRP Ltd](https://www.sectoralpha.in/stocks/grp-ltd) ₹1,029 crore · Rubber Processing/Rubber Products

## What else do people ask about Bajaj Healthcare? ### What were Bajaj Healthcare's latest quarterly results? Bajaj Healthcare Ltd reported revenue of ₹176 Cr and net profit of ₹14.0 Cr for the Sep 2026 quarter. Revenue rose 18.9% and profit rose 27.3% compared with a year earlier. Earnings per share were ₹4.19. The operating margin was 18.0%, 0.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Bajaj Healthcare's market cap? Bajaj Healthcare Ltd's market capitalisation is ₹1,031 Cr at a share price of ₹306.10. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Bajaj Healthcare performing? Bajaj Healthcare Ltd's share price has been falling for 66 weeks. In its latest quarter, revenue rose 18.9% and profit rose 27.3% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 1 week running (as of 3 November 2026). ### Will Bajaj Healthcare's share price go up? This page does not forecast Bajaj Healthcare Ltd's share price. What it shows instead: the share price is ₹306.10, and it has been falling for 66 weeks. Its P/E of 17.7× is higher than 38% of its own last 11 years (as of 3 November 2026). ### Who owns Bajaj Healthcare? Promoters own 58.6% of Bajaj Healthcare Ltd, foreign institutions 2.1%, domestic institutions 2.0% and the public 37.4% (latest quarter). The biggest change over the last two years: Foreign institutions raised their stake by 1.0 percentage points over 8 quarters (as of 3 November 2026). ### Does Bajaj Healthcare have too much debt? Bajaj Healthcare Ltd has a moderate amount of debt: its debt is 0.47× its equity, and its operating profit is 5 times its interest bill. FY26 borrowings were ₹249 Cr against equity of ₹533 Cr. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### What is Bajaj Healthcare's capex? Bajaj Healthcare Ltd sold more long-term assets (plants, machines and the like) than it bought over the last 3 years, by ₹48.0 Cr, worked out from the change in fixed assets plus depreciation. Depreciation over the same years was ₹84.0 Cr (as of 3 November 2026). ### Where is Bajaj Healthcare in its business cycle? Bajaj Healthcare Ltd's FY26 operating margin was 17.0%, against a 13-year range of 9.0% to 21.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 18.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Bajaj Healthcare story? The main question: profits are rising, but only 59% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Bajaj Healthcare a stock worth studying right now? What the numbers show: Bajaj Healthcare Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Bajaj Healthcare share price forecast for 2026? What management itself guided: FY29 revenue ₹900-1,000 crore and operating margin 18%-21%. ## Lists

- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.